Get informed when a big investor buys or sells
+ FollowLoading insider trades…
Loading congress trades…
| Market cap | $5,364.00 |
|---|---|
| Enterprise Value | $-3,156,636.00 |
| Earnings per Share | $-0.7 |
| Beta | -4.26 |
| Outstanding Shares | 53,640,000 |
| P/E Ratio | 0 |
|---|---|
| PEG | 0 |
| Price to Sales | - |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | -31.89 |
| Enterprise Value to EBIT | 0.09 |
| Enterprise Value to Net Income | 0 |
| Total Debt to Enterprise | -5.77 |
| Debt to Equity | 3.45 |
No data
No data available for the latest quarter.
No data available for the latest quarter.
Panacos Pharmaceuticals, Inc. functions as an early-stage biotechnology firm specializing in the research and development of orally administered small-molecule therapeutics. These innovative drugs are crafted to combat human immunodefici...